PATENT CLAIM ANALYSIS

Application Number: 15744485
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "492000"]

Abstract:
Methods for reducing platinum drug-induced toxicity in a cell expressing Organic Cation Transporter 2 (OCT2), methods for reducing platinum drug-induced toxicity in a subject, methods for treating cancer, methods for increasing efficacy of platinum drug treatment in a subject, and pharmaceutical compositions are described. The described methods and compositions include an OCT2 inhibitor where the OCT2 inhibitor is buflomedil or a salt thereof, dolutegravir or a salt thereof contains an imidazole, or is miconazole or a salt thereof.

Claim (Index 26):
The method of  claim 25 , wherein the dose of buflomedil or a buflomedil salt administered in a subject is adjusted based on at least one of the factors of the said subject, body weight, body surface area, height, age, gender, alcohol use, tobacco use, life style, renal function, liver function, genetic polymorphism and co-medications.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 86.0
- Lexical Diversity: 1.83333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12836398', '13147751', '14175295', '11638193', '15314200']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7860537834387218
- 35 USC 102 Novelty (BERT): 0.5140395335719661
- Combined Prediction Score: 0.7588523584520462
- Mean Citation Score: 256.733086
- Max Citation Score: 260.66200000000003
- Similarity Product: 160.94178975188734

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test